A phase II study of RAD001 (everolimus) for children with chemotherapy hemotherapy-refractory progressive symptomatic low grade gliomas

Principal Investigator: Mark W. Kieran, MD, PhD

Institute: Dana-Farber Cancer Institute

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Boston, MA

Share